ATHA · Categories · Form 4
ATHA - SEC Form 4 insider transactions
Athira Pharma Inc. (ATHA) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.
Recent Form 4 for ATHA
- CHIEF MEDICAL OFFICER San Martin Javier converted options into 4,667 shares and sold $11,311 worth of shares (1,644 units at $6.88), increasing direct ownership by 42% to 10,189 units (SEC Form 4)4 - Athira Pharma, Inc. (0001620463) (Issuer)
- President and CEO Litton Mark James sold $17,792 worth of shares (2,586 units at $6.88) and converted options into 10,834 shares, increasing direct ownership by 25% to 40,828 units (SEC Form 4)4 - Athira Pharma, Inc. (0001620463) (Issuer)
- Chief Financial Officer Renninger Robert was granted 1,000 shares, converted options into 1,236 shares and sold $2,043 worth of shares (297 units at $6.88), increasing direct ownership by 18% to 12,857 units (SEC Form 4)4 - Athira Pharma, Inc. (0001620463) (Issuer)
- CHIEF SCIENTIFIC OFFICER Church Kevin was granted 1,000 shares, converted options into 3,667 shares and sold $6,027 worth of shares (876 units at $6.88), increasing direct ownership by 22% to 20,681 units (SEC Form 4)4 - Athira Pharma, Inc. (0001620463) (Issuer)
- General Counsel and CCO Worthington Mark converted options into 3,667 shares and sold $6,027 worth of shares (876 units at $6.88), increasing direct ownership by 25% to 13,978 units (SEC Form 4)4 - Athira Pharma, Inc. (0001620463) (Issuer)
- SEC Form 4 filed by Chief Financial Officer Renninger Robert4 - Athira Pharma, Inc. (0001620463) (Issuer)
- SEC Form 4 filed by President and CEO Litton Mark James4 - Athira Pharma, Inc. (0001620463) (Issuer)
- SEC Form 4 filed by CHIEF SCIENTIFIC OFFICER Church Kevin4 - Athira Pharma, Inc. (0001620463) (Issuer)
- SEC Form 4 filed by CHIEF MEDICAL OFFICER San Martin Javier4 - Athira Pharma, Inc. (0001620463) (Issuer)
- SEC Form 4 filed by General Counsel and CCO Worthington Mark4 - Athira Pharma, Inc. (0001620463) (Issuer)
- Director Perceptive Advisors Llc was granted 1,319,026 shares (SEC Form 4)4 - Athira Pharma, Inc. (0001620463) (Issuer)
- CHIEF SCIENTIFIC OFFICER Church Kevin was granted 10,000 shares, converted options into 36,666 shares and sold $2,502 worth of shares (8,526 units at $0.29), increasing direct ownership by 29% to 168,901 units (SEC Form 4)4 - Athira Pharma, Inc. (0001620463) (Issuer)
- President and CEO Litton Mark James converted options into 108,334 shares and sold $7,374 worth of shares (25,123 units at $0.29), increasing direct ownership by 34% to 325,802 units (SEC Form 4)4 - Athira Pharma, Inc. (0001620463) (Issuer)
- CHIEF MEDICAL OFFICER San Martin Javier converted options into 46,666 shares and sold $3,182 worth of shares (10,842 units at $0.29), increasing direct ownership by 100% to 71,665 units (SEC Form 4)4 - Athira Pharma, Inc. (0001620463) (Issuer)
- General Counsel and CCO Worthington Mark converted options into 36,666 shares and sold $2,502 worth of shares (8,526 units at $0.29), increasing direct ownership by 34% to 111,875 units (SEC Form 4)4 - Athira Pharma, Inc. (0001620463) (Issuer)
- SVP, Finance and Accounting Renninger Robert converted options into 12,359 shares, sold $850 worth of shares (2,897 units at $0.29) and was granted 10,000 shares, increasing direct ownership by 22% to 109,186 units (SEC Form 4)4 - Athira Pharma, Inc. (0001620463) (Issuer)
- SEC Form 4 filed by Director Fluke John M Jr4 - Athira Pharma, Inc. (0001620463) (Issuer)
- SEC Form 4 filed by Director Panzara Michael A.4 - Athira Pharma, Inc. (0001620463) (Issuer)
- SEC Form 4 filed by Director Romano Kelly A4 - Athira Pharma, Inc. (0001620463) (Issuer)
- SEC Form 4 filed by Director Edelman Joseph4 - Athira Pharma, Inc. (0001620463) (Issuer)
- SEC Form 4 filed by Director Johnson James A4 - Athira Pharma, Inc. (0001620463) (Issuer)
- SEC Form 4 filed by Director Kosacz Barbara4 - Athira Pharma, Inc. (0001620463) (Issuer)
- SEC Form 4 filed by Director Pickering Grant4 - Athira Pharma, Inc. (0001620463) (Issuer)
- Amendment: SEC Form 4 filed by SVP, Finance and Accounting Renninger Robert4/A - Athira Pharma, Inc. (0001620463) (Issuer)
- SEC Form 4 filed by SVP, Finance and Accounting Renninger Robert4 - Athira Pharma, Inc. (0001620463) (Issuer)
- SEC Form 4 filed by CHIEF SCIENTIFIC OFFICER Church Kevin4 - Athira Pharma, Inc. (0001620463) (Issuer)
- SEC Form 4 filed by President and CEO Litton Mark James4 - Athira Pharma, Inc. (0001620463) (Issuer)
- SEC Form 4 filed by CHIEF MEDICAL OFFICER San Martin Javier4 - Athira Pharma, Inc. (0001620463) (Issuer)
- SEC Form 4 filed by General Counsel and CCO Worthington Mark4 - Athira Pharma, Inc. (0001620463) (Issuer)
- CHIEF MEDICAL OFFICER San Martin Javier converted options into 46,667 shares and sold $6,083 worth of shares (10,826 units at $0.56) (SEC Form 4)4 - Athira Pharma, Inc. (0001620463) (Issuer)
- President and CEO Litton Mark James converted options into 108,333 shares and sold $14,108 worth of shares (25,107 units at $0.56), increasing direct ownership by 52% to 242,591 units (SEC Form 4)4 - Athira Pharma, Inc. (0001620463) (Issuer)
- CHIEF SCIENTIFIC OFFICER Church Kevin was granted 9,920 shares, converted options into 36,667 shares and sold $4,782 worth of shares (8,510 units at $0.56), increasing direct ownership by 41% to 130,761 units (SEC Form 4)4 - Athira Pharma, Inc. (0001620463) (Issuer)
- VP of Finance Renninger Robert was granted 3,651 shares, converted options into 12,359 shares and sold $1,619 worth of shares (2,881 units at $0.56), increasing direct ownership by 17% to 89,724 units (SEC Form 4)4 - Athira Pharma, Inc. (0001620463) (Issuer)
- General Counsel and CCO Worthington Mark was granted 3,651 shares, converted options into 36,667 shares and sold $4,782 worth of shares (8,510 units at $0.56), increasing direct ownership by 61% to 83,735 units (SEC Form 4)4 - Athira Pharma, Inc. (0001620463) (Issuer)
- Amendment: SEC Form 4 filed by President and CEO Litton Mark James4/A - Athira Pharma, Inc. (0001620463) (Issuer)
- SEC Form 4 filed by VP of Finance Renninger Robert4 - Athira Pharma, Inc. (0001620463) (Issuer)
- SEC Form 4 filed by CHIEF MEDICAL OFFICER San Martin Javier4 - Athira Pharma, Inc. (0001620463) (Issuer)
- SEC Form 4 filed by CHIEF SCIENTIFIC OFFICER Church Kevin4 - Athira Pharma, Inc. (0001620463) (Issuer)
- SEC Form 4 filed by General Counsel and CCO Worthington Mark4 - Athira Pharma, Inc. (0001620463) (Issuer)
- SEC Form 4 filed by President and CEO Litton Mark James4 - Athira Pharma, Inc. (0001620463) (Issuer)
- CFO and Chief Business Officer Gengos Andrew was granted 15,000 shares and sold $720 worth of shares (1,272 units at $0.57), increasing direct ownership by 16% to 97,532 units (SEC Form 4)4 - Athira Pharma, Inc. (0001620463) (Issuer)
- COO and CDO Lenington Rachel was granted 10,000 shares and sold $1,429 worth of shares (2,525 units at $0.57), increasing direct ownership by 56% to 20,870 units (SEC Form 4)4 - Athira Pharma, Inc. (0001620463) (Issuer)
- CHIEF SCIENTIFIC OFFICER Church Kevin was granted 14,953 shares and sold $1,429 worth of shares (2,525 units at $0.57), increasing direct ownership by 15% to 92,684 units (SEC Form 4)4 - Athira Pharma, Inc. (0001620463) (Issuer)
- GENERAL COUNSEL Worthington Mark was granted 20,000 shares and sold $1,429 worth of shares (2,525 units at $0.57), increasing direct ownership by 51% to 51,927 units (SEC Form 4)4 - Athira Pharma, Inc. (0001620463) (Issuer)
- President and CEO Litton Mark James was granted 20,000 shares and sold $2,848 worth of shares (5,032 units at $0.57), increasing direct ownership by 10% to 159,365 units (SEC Form 4)4 - Athira Pharma, Inc. (0001620463) (Issuer)
- SEC Form 4 filed by Romano Kelly A4 - Athira Pharma, Inc. (0001620463) (Issuer)
- SEC Form 4 filed by Edelman Joseph4 - Athira Pharma, Inc. (0001620463) (Issuer)
- SEC Form 4 filed by Johnson James A4 - Athira Pharma, Inc. (0001620463) (Issuer)
- SEC Form 4 filed by Kosacz Barbara4 - Athira Pharma, Inc. (0001620463) (Issuer)
- SEC Form 4 filed by Panzara Michael A.4 - Athira Pharma, Inc. (0001620463) (Issuer)
- SEC Form 4 filed by Pickering Grant4 - Athira Pharma, Inc. (0001620463) (Issuer)
- SEC Form 4 filed by Fluke John M Jr4 - Athira Pharma, Inc. (0001620463) (Issuer)
- SEC Form 4 filed by San Martin Javier4 - Athira Pharma, Inc. (0001620463) (Issuer)
- SEC Form 4 filed by Litton Mark James4 - Athira Pharma, Inc. (0001620463) (Issuer)
- SEC Form 4 filed by Worthington Mark4 - Athira Pharma, Inc. (0001620463) (Issuer)
- SEC Form 4 filed by Church Kevin4 - Athira Pharma, Inc. (0001620463) (Issuer)
- SEC Form 4 filed by Gengos Andrew4 - Athira Pharma, Inc. (0001620463) (Issuer)
- SEC Form 4 filed by Lenington Rachel4 - Athira Pharma, Inc. (0001620463) (Issuer)
- Lenington Rachel was granted 10,000 shares and sold $7,019 worth of shares (2,412 units at $2.91), increasing direct ownership by 131% to 13,395 units (SEC Form 4) (Amendment)4/A - Athira Pharma, Inc. (0001620463) (Issuer)
- Litton Mark James was granted 20,000 shares and sold $14,026 worth of shares (4,820 units at $2.91), increasing direct ownership by 12% to 144,397 units (SEC Form 4) (Amendment)4/A - Athira Pharma, Inc. (0001620463) (Issuer)